このエントリーをはてなブックマークに追加
ID 56080
JaLCDOI
FullText URL
Thumnail 72_3_319.pdf 1.99 MB
Author
Makimoto, Go Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Ichihara, Eiki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Hotta, Katsuyuki Center of Innovative Clinical Medicine, Okayama University Hospital
Ninomiya, Kiichiro Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Oze, Isao Division of Epidemiology and Prevention, Aichi Cancer Center
Minami, Daisuke Department of Respiratory Medicine, Okayama Medical Center
Ninomiya, Takashi Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kubo, Toshio Center for Clinical Oncology, Okayama University Hospital
Ohashi, Kadoaki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Tabata, Masahiro Center for Clinical Oncology, Okayama University Hospital
Maeda, Yoshinobu Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital
Abstract
Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
Keywords
cisplatin
mannitol
furosemide
lung cancer
hydration
non-small cell lung cancer
Amo Type
Clinical Study Protocol
Published Date
2018-06
Publication Title
Acta Medica Okayama
Volume
volume72
Issue
issue3
Publisher
Okayama University Medical School
Start Page
319
End Page
323
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2018 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID